

Dentons Flashpoint

Daily Global Situation Report

September 30, 2020

Global Situation Update: September 30, 2020

KEY TAKEAWAYS

Kuwait's Emir Sheikh Sabah died, aged 91.

South Africa's working population shrank by 2m during lockdown.

A preliminary South Korean study shows enduring side effects after recovery in 9 out of 10 COVID-19 patients.

Global

Overnight, confirmed coronavirus cases rose to 33,872,977 in 213 countries and territories, with 1,013,146 deaths.

- The World Bank is set to offer \$12bn in cheap financing to help low-income countries purchase **vaccines**.
- The chief executive of the world's largest **vaccine** maker, GlaxoSmithKline, said she is optimistic the industry will make a COVID-19 immunization widely available next year.
- The GAVI **vaccine** alliance agrees on a new partnership with the Serum Institute of India to make an extra 100m doses of vaccine available to low-income countries.
- The US National Institutes of Health reported that the **vaccine** developed by researchers at NIAID and Moderna is generating a “*strong immune response*” in older adults.

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Markets

The renminbi is set to notch its best quarter since the global financial crisis, helped by a sell-off in the dollar.

- On Wednesday, **European stocks** slipped as surging coronavirus cases and a chaotic US presidential debate sapped risk appetite.
- **Asia-Pacific stocks** were mixed as investors reacted to China's manufacturing activity data and the US presidential debate.
- **US stocks** broke their three-day winning streak Tuesday as concern about the coronavirus pandemic and elections weighed on investors.
- Brent **crude** closed down 3.3 percent as traders said optimism about demand recovery had waned.
- The US Conference Board's **consumer confidence** index jumped in September as more Americans expect an increase in the number of available jobs in coming months.
- **US house prices** rose at an annual pace of over 4 percent for the sixth straight month.
- **Harvard University's endowment** saw a top-notch return of 7.3 percent in the fiscal year ending in June.

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Business

Singapore Airlines is turning its A380 into a fine-dining restaurant as it seeks novel forms of income.

- A **KPMG** probe found that an internal whistleblower at **EY** had raised fraud allegations against **Wirecard** in 2016.
- Poland's ecommerce company **Allegro** is set to mark the country's biggest ever IPO.
- **Disney** has said it will lay off about 28,000 employees in US theme parks due to the pandemic.
- **JPMorgan Chase** agreed to pay \$920m and admit to misconduct for manipulation of precious-metals and Treasury markets.
- **Marathon Petroleum** reportedly began cutting jobs across the company.
- **Micron Technology** forecast a lower than expected quarterly income, in part due to the impact of US bans on chip exports to **Huawei**.
- **Royal Dutch Shell** plans to cut up to 9,000 job cuts, restructuring to shift to an era of cleaner fuels.
- A resurgence in **mergers and acquisitions** activity led to the busiest summer for blockbuster deals in three decades; with a combined value of \$5bn-plus, deals worldwide soared to \$456bn in the three months to September, according to figures from Refinitiv.
- The EU is reportedly set to approve **Google's** \$2.1bn deal for **Fitbit**.

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Africa

- **South Africa's** working population shrank by 2m during lockdown, the country's biggest workforce fall in history.
- **Rwanda's** strict and high-tech COVID-19 response has been applauded for effectiveness (only 4,800 cases and 29 deaths have been registered since March), but critics warn that civil liberties are being endangered.
- **Togo's** President appointed the country's first ever female PM this week, Victoire Tomegah Dogbe.
- The World Food Programme has been providing assistance to over 500,000 people in **South Sudan** as the threat of famine there climbs.



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Asia


- **North Korea** told the UN that it has a “*reliable and effective war deterrent for self-defense*” and will now focus on developing its economy.
- A preliminary study in **South Korea** found that 9 in 10 COVID-19 patients reported continued side effects after recovery, including fatigue and loss of smell.
- New measures in **Australia** seek to incentivize farm work for young job seekers as the pandemic continues to cause a shortage of foreign workers.
- **Vietnam’s** government said that real GDP rose 2.62 percent in Q3.
- The average land price in **Japan** fell 0.6 percent, the first drop in three years.
- The Asian Development Bank has announced it will lend \$15m to **Mongolian** to curb rising wheat prices.
- A World Bank report said that the pandemic has brought down **East Asia** growth rates to levels not seen since 1967.
- The global soccer players union warned that **Asian** clubs are particularly vulnerable to wage reductions and job losses amid the pandemic.
- **Thailand** will receive its first **Chinese** tourists next week as the tourism industry begins a cautious reopening.
- **China’s** manufacturing sector expanded at a faster pace than forecast in September, as export orders grew. China is preparing to launch an antitrust probe into Alphabet Inc’s Google, looking into allegations it has leveraged the dominance of its Android mobile operating system to stifle competition



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Europe

- **Armenia** said one of its fighter jets was shot down by a **Turkish** jet in a major escalation of the Nagorno-Karabakh conflict.
- **Hungarian** PM Orban demanded the resignation of the EU's justice commissioner, who has called Hungary a “*sick democracy*.”
- The **UK and Canada** imposed sanctions against **Belarusian** President Lukashenko; this is the first time the UK has targeted a national leader with its own sanctions. **French** President Macron met with Belarusian opposition leader Svetlana Tikhanovskaya.
- **Spain's** government plans to implement new COVID-19 restrictions throughout the country; the Madrid region has logged over 51,000 cases in the past two weeks alone.
- **Germany** is set to impose tighter restrictions on social gatherings as Chancellor Merkel warned the country could reach over 19,000 daily infections by Christmas.
- **Ireland** warned that a no-deal Brexit would strip three percentage points from its economic recovery from the pandemic.
- A property industry body said that £2bn of **UK** retail rents have likely gone unpaid. The UK education secretary announced that university students will be able to return home for Christmas. UK Home Secretary Patel has asked officials to explore constructing an asylum processing center on the distant British overseas territory of Ascension Island. The UK recorded a record daily case rise and its highest daily death toll since July 1.



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Middle East


- **Kuwait's** Emir Sheikh Sabah al-Ahmad al-Sabah, who had ruled the country since 2006, died Tuesday at age 91; Sheikh Sabah's half-brother Crown Prince Nawaf al-Ahmed al-Jaber al-Sabah is expected to become the new emir.
- A UN report said that the **UAE** increased delivery of military supplies to eastern **Libyan** General Haftar in violation of the arms embargo on Libya. Libyans took to the streets in the city of Tajoura to protest the presence of militias.
- **Israel's** PM Netanyahu accused Hizballah of improperly storing weapons in a civilian area near Beirut, **Lebanon**.
- **Jordan** surpassed 10,000 virus cases.



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Americas



- **Mexico** increased its “estimated” COVID-19 deaths to 89,612 and boosted estimated cases by 137,000. Mexico launched a special guard force to protect mining companies, many of which are foreign, that drug cartels have preyed on.
- **Guatemala’s** government will allow the official reopening of bars, national parks and gyms this week.
- The **Colombian** navy said 94 **Haitian** migrants who were stuck at sea have been rescued.
- **Trinidad** canceled its famous carnival for 2021 due to the coronavirus.
- Over 100 activists in **Peru’s** Amazon occupied state-run Petroperu pipeline infrastructure, demanding improved social and health benefits amid the pandemic.



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Americas

Canada's federal government and two largest provinces promised new anti-virus measures as cases rose back to levels seen in April. Total confirmed cases reported as of yesterday are 158,991, with 9,340 deaths. The rate of increase for new cases over the past 7 days averaged 5.69 percent




Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Americas: US

- The FDA chief asserted that his officials would assess any **vaccine** candidate by a set of guidelines that experts say would make approving a vaccine before the election almost impossible, including the criteria that companies must monitor trial patents for at least two months before applying for approval. State leaders say the Trump Administration's rollout of **rapid testing** is plagued by poor communication, false results, and lack of planning.
- Joe Biden and Kamala Harris released their **tax returns** ahead of Tuesday's debate as President Trump continues to face scrutiny over tax records published by the *New York Times*. President Trump and Democratic challenger Joe Biden clashed in an unruly **debate** breaking all the norms, a spectacle of the on-going culture and class war.
- **New York** City's test positivity rate hit a multi-month high of just over 3 percent; New York City will begin fining people who refuse to wear a mask. The **Tennessee** Titans and **Minnesota** Vikings suspended team activities on Tuesday after a number of positive COVID-19 tests following their Sunday game in the third week of the **NFL's** 2020 season. Analysis shows that cases among young adults rose steadily in recent weeks as **universities** reopened.
- New York City will resend almost 100,000 absentee ballots after a printing error that could invalidate some votes. US security officials are warning that domestic extremists pose a significant threat to the **coming election**.
- The Treasury Department said Tuesday it would start forgiving **PPP loans**. House Speaker Pelosi said she hopes for a **coronavirus aid deal** by the end of the week.
- More than 100 wineries in Napa Valley are at risk of burning as **catastrophic California fires** continue to burn.
- Kentucky Attorney General Daniel Cameron did not recommend murder charges to the grand jury considering evidence against the police officers involved in the **death of Breonna Taylor**, he said Tuesday amid growing criticism of his handling of the case.



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

The Phase II Vaccine Tracker



Vaccine development continues to be one of the most watched news stories of the year, as widespread vaccination seems increasingly likely to be the only exit ramp from the coronavirus pandemic in many parts of the world. While vaccine development may feel slow-moving given the urgency of need for a COVID-19 vaccine, the current processes have been dramatically accelerated to meet the moment of this unprecedented pandemic. Moreover, the wide array of vaccine candidates undergoing trials ensure that the roadmap to mass vaccination is frequently changing. Just last week, two candidates (Novavax and Johnson & Johnson) moved into Phase 3 trials, one candidate (Vaxart) entered initial Phase 1 trials, and another (SpyBiotech) entered combined 1/2 trials. The vaccine candidates furthest along in the approval process have already reached Phase 3 trials, in which a large number of people are vaccinated to test the effectiveness and further safety of vaccine candidates. Some vaccine candidates from Russia and China have even been approved for limited or early use. (For a full tracker of Phase 3 vaccines, see the Dentons Flashpoint [September 25 edition](#))

While Phase 3 candidates may be closest to the prospect of approval, many promising vaccines can also be found in Phase 2 trials. In Phase 2 trials, scientists administer vaccine doses to hundreds of people split into different groups, such as children and the elderly, to test the vaccine's effects and safety. Many vaccines are also in combined Phase 1/2 or Phase 2/3 trials, which serves as one way to accelerate vaccine development. Examining the vaccine candidates that are currently in Phase 2 or combined Phase 1/2 trials give a broader picture of possible vaccines that may begin production next year. Moreover, looking at Phase 2 trials presents a broader picture of where vaccines are being developed. While Phase 3 trials are being conducted across many parts of the world, with a diverse array of public health partnerships, the candidates under testing have been developed by companies and institutes in a select few of countries: China, the UK, the US, Australia, Germany, and Russia. Vaccines in Phase 2 expand that geography to include candidates developed in India, Cuba, France, Japan and Singapore.

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

The Phase II Vaccine Tracker

Where vaccines are undergoing phase 2 testing



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

The Phase II Vaccine Tracker





Though health experts have emphasized the need to depoliticize vaccine development and put public health concerns above geopolitics, a vaccine's country of origin promises to be highly significant.

Along with being a source of national pride and opportunity to expand soft power and foreign policy goals, how vaccines will be distributed across countries remains a question of great concern. Vaccine deal making by a group of some the world's richest nations – including the US, UK, EU and Japan – has meant that a bloc representing 13 percent of the world's population has bought more than half of top vaccine candidates' promised doses, according to Oxfam. The leading solution for global vaccine distribution is the COVAX facility, which aims to support the development and equitable global distribution of 2 billion vaccine doses before the end of 2021. As of early last week, 64 higher income countries have joined the COVAX facility, while 92 low- and middle- income countries will be eligible for support, creating a total of 156 economies involved that represent almost two-thirds of the global

population. However, key countries remain reticent to join, including the US and China. (For more details on the COVAX facility, see the Dentons Flashpoint [August 14 edition](#)).









Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

The Phase II Vaccine Tracker

Vaccine Candidate	Sponsor		Trial Phase	Country	Further Details
ZyCov-D	Zydus Cadila		Phase 2	India	This DNA-based vaccine began trials in July, entering Phase 2 on August 6.
CVnCoV	CureVac		Phase 2	Germany	CureVac launched a Phase 1 trial in June and a Phase 2 trial in August. CureVac hopes to make 100 million doses by the end of 2020 and gain approval sometime in 2021. CureVac has collaborated with Tesla on creating “micro-factories” to manufacture doses worldwide.
No name announced	Morningside Ventures; Imperial College London	 	Combined Phases 1/2	UK	Imperial College London’s RNA vaccine candidate began combined Phase 1/2 trials on June 15 and will partner with Morningside Ventures through a new company called VacEquity Global Health for manufacturing and distribution. Researchers expect to assess vaccine efficacy by end 2020.



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

The Phase II Vaccine Tracker

Vaccine Candidate	Sponsor		Trial Phase	Country	Further Details
AG0301-COVID19	AnGes; Osaka University; Takara Bio	  	Combined Phases 1/2	Japan	AnGes announced the start of Phase 1 trials for their DNA-based vaccine candidate on June 30, and began recruiting at the end of August.
LUNAR-COV19 (ARCT-021)	Arcturus Therapeutics; Duke-NUS Medical School	 	Combined Phases 1/2	US; Singapore	The Phase 1/2 trial of this mRNA vaccine candidate began in August at Singapore General Hospital.
No name announced	Anhui Zhifei Longcom; Chinese Academy of Medical Sciences	 <p>INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES</p> 	Phase 2	China	Phase 2 trials began in July.
Soberana 1	Finlay Vaccine Institute		Combined Phases 1/2	Cuba	Cuba's health ministry announced clinical trials on August 18.



Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

The Phase II Vaccine Tracker

Vaccine Candidate	Sponsor		Trial Phase	Country	Further Details
<i>EpiVacCorona</i>	Vector Institute		Combined Phases 1/2	Russia	The vaccine candidate registered Phase 1/2 trials on August 26; newspaper reports indicate plans for distribution by the end of 2020
<i>No name announced</i>	Sanofi; GSK		Combined 1/2 phases	France; UK	Sanofi's vaccine candidate based on viral proteins entered Phase 1/2 trials in September and plans to enter Phase 3 in December. Sanofi has already negotiated major deals to deliver 100m doses to the US, 300m to the EU, 72m to Canada, and many more to the COVAX facility. The plan to make 1bn doses in 2021.
<i>No name discovered</i>	SpyBiotech		Combined Phase 1/2	UK; Partners in India, Australia	Trials began in September in Australia, run by the Serum Institute of India.
<i>No name discovered</i>	Institute of Medical Biology at the Chinese Academy of Medical Sciences		Phase 2	China	Phase 2 trials began in June.

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

The Phase II Vaccine Tracker

Vaccine Candidate	Sponsor		Trial Phase	Country	Further Details
Covaxin	Indian Council of Medical Research; National Institute of Virology; Bharat Biotech		Combined Phases 1/2	India	Phase 1/2 trials began in July; reports initially circulated that the vaccine would be ready in August, but Bharat's CEO has said it will be ready no earlier than 2021.
AZD1222	AstraZeneca; Univ. of Oxford; IQVIA; Serum Institute of India		Combined Phases 2/3	UK	Phase 2/3 trials are underway in the UK and India, and Phase 3 trials in Brazil, South Africa, and the US. AstraZeneca halted trials on September 6 to investigate the illness of one volunteer; British and Brazilian trials resumed one week later but other trials remain on hold. AstraZeneca has indicated emergency vaccine delivery might be able to start in October 2020 (depending on trial results) and has said that manufacturing capacity stands at 2 billion doses if approved. The US in May awarded \$1.2 billion in support for the candidate, and the EU in August agreed to acquire 400 million doses if the vaccine proves safe and effective.

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.


The Phase II Vaccine Tracker

Vaccine Candidate	Sponsor		Trial Phase	Country	Further Details
<i>Bacillus Calmette-Guerin (BCG) vaccine</i>	Univ. of Melbourne and Murdoch Children's Research Institute; Radboud Univ. Medical Center; Massachusetts General Hospital		Combined Phases 2/3	Australia; Netherlands; USA	The Murdoch Children's Research Institute in Australia is conducting Phase 3 trials to see if a vaccine developed in the early 1900s to fight tuberculosis, the Bacillus Calmette-Guerin vaccine (BRACE), may partly protect against the coronavirus.
<i>BNT162</i>	Pfizer, BioNTech		Combined Phases 2/3	Germany, US, China; Multiple study sites in Europe and North America	Combined Phase 2/3 trials for this mRNA candidate were launched in July with 30,000 volunteers in the US and other countries; in September, an intended expansion of US volunteers to 43,000 was announced. Pfizer's chief executive believes the vaccine's efficacy will be known by October 2020, and if approved, Pfizer expects to manufacture over 1.3 billion doses by the end of 2021. The US government has agreed to pay \$1.9bn for 100 million doses to be delivered by December with the option to acquire 500 million more later, Japan has agreed to acquire 120 million doses, and the EU has made a deal for 200 million doses.

Coronavirus Condition Updates

As of 2100 hours US EDT on September 29


Confirmed Cases (New)



Reflects data as of 2100 hours the evening before the date of the situation report.
Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.


Total Deaths (New)



Reflects data as of 2100 hours the evening before the date of the situation report.
Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Active Cases



Reflects data as of 2100 hours the evening before the date of the situation report.
Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Country Risk Assessment

VERY HIGH RISK (>5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases / 1M Pop.	Deaths / 1M Pop	% Daily Change7-Day Av
US	4122447	7137932 (40983)	205263 (900)	22342	636	3.51%
India	947576	6145291 (0)	96318 (0)	4499	71	8.12%
Spain	566479	748266 (0)	31411 (0)	16214	676	7.31%
France	454301	564690 (11858)	31711 (162)	8432	488	14.30%
UK	404150	447551 (7152)	42144 (71)	6564	619	8.15%
Brazil	397449	4777522 (32058)	142921 (863)	22450	672	3.90%
Russia	192987	1162428 (8129)	20456 (157)	8001	141	3.87%
Argentina	134233	736609 (13477)	16519 (406)	16261	365	9.75%
Ukraine	112491	210309 (3730)	4154 (72)	4693	93	9.90%
Netherlands	111158	117551 (6880)	6393 (27)	6857	373	14.42%
Peru	105401	808714 (3412)	32324 (62)	24536	979	3.98%
Belgium	87728	117115 (1762)	10001 (14)	9942	861	8.73%
Sweden	86576	92466 (1543)	5890 (10)	9142	582	2.93%
Bangladesh	83126	362043 (1488)	5219 (26)	2193	32	2.26%

Data Source: Johns Hopkins University

VERY HIGH RISK (>5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases/ 1M Pop.	Deaths/ 1M Pop	% Daily Change7-Day Av
Israel	67594	236926 (3661)	1528 (21)	25760	166	13.61%
Colombia	64060	824042 (5839)	25828 (187)	16153	506	4.83%
Indonesia	61686	282724 (4002)	10601 (128)	1031	39	8.96%
Iraq	60356	358290 (4724)	9122 (70)	8860	226	7.16%
Philippines	50925	309303 (2015)	5448 (67)	2813	50	4.76%
Italy	50630	313011 (1647)	35875 (24)	5179	594	3.35%
South Africa	49385	672572 (903)	16667 (81)	11305	280	1.10%
Iran	48924	453637 (3677)	25986 (207)	5384	308	4.59%
Puerto Rico	47813	48467 (1045)	654 (6)	14310	193	11.98%
Honduras	46392	76098 (561)	2323 (22)	7597	231	4.50%
Costa Rica	43021	74604 (890)	880 (19)	14612	172	8.77%
Ethiopia	42441	74584 (640)	1191 (14)	645	10	4.69%
Mexico	35488	738163 (4446)	77163 (560)	5676	593	3.81%
Czechia	34448	67843 (1960)	636 (18)	6332	59	18.25%

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.



Country Risk Assessment

VERY HIGH RISK (>5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases / 1M Pop.	Deaths / 1M Pop	% Daily Change 7-Day Av
Serbia	32730	33479 (65)	749 (1)	3836	86	1.19%
Bolivia	31815	134641 (418)	7931 (31)	11460	675	1.97%
Turkey	30638	317272 (1427)	8130 (68)	3752	96	2.90%
Germany	25776	290471 (1840)	9483 (15)	3464	114	3.94%
Portugal	24561	74717 (688)	1963 (6)	7333	193	5.69%
Dominican Rep	22801	111900 (234)	2101 (3)	10290	193	1.93%
Panama	21287	111853 (576)	2364 (16)	25824	546	3.45%
Lebanon	20906	38377 (1105)	361 (10)	5629	53	17.16%
Nepal	20396	76258 (1513)	491 (10)	2606	17	11.09%
Romania	19986	125414 (1470)	4792 (44)	6530	250	7.18%
Hungary	19637	25567 (851)	757 (8)	2648	78	20.01%
Morocco	18778	121183 (2076)	2152 (39)	3274	58	11.09%
Poland	18524	89962 (1326)	2483 (36)	2378	66	9.21%
Greece	16388	18123 (416)	388 (5)	1741	37	10.14%

VERY HIGH RISK (>5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases/ 1M Pop	Deaths/ 1M Pop	% Daily Change 7-Day Av
Paraguay	15512	40101 (669)	841 (23)	5605	118	11.30%
Libya	14572	34014 (801)	540 (13)	4934	78	11.52%
Canada	13886	158991 (1772)	9340 (12)	4150	246	5.69%
Chile	13781	461300 (1629)	12725 (27)	24080	664	2.47%
Algeria	13579	51368 (155)	1726 (7)	1166	39	1.88%
Kenya	12931	38378 (210)	707 (7)	710	13	2.68%
Ecuador	12141	135749 (784)	11312 (32)	7666	639	4.31%
Moldova	12140	52029 (835)	1310 (9)	12905	325	7.30%
Tunisia	12127	17405 (1291)	246 (32)	1469	21	28.30%
Saudi Arabia	10906	334187 (539)	4739 (27)	9563	136	0.85%
Ireland	10573	35740 (363)	1803 (1)	7218	364	5.78%
UAE	10136	93090 (995)	416 (3)	9384	42	5.97%
Venezuela	9542	74363 (835)	621 (7)	2617	22	6.62%
Oman	9122	98585 (528)	935 (11)	19189	182	3.29%

Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Country Risk Assessment

VERY HIGH RISK (>5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases / 1M Pop.	Deaths / 1M Pop	% Daily Change 7-Day Av
Pakistan	8903	312263 (747)	6479 (5)	1404	29	1.30%
Myanmar	8750	12425 (794)	284 (28)	228	5	37.01%
Austria	8329	44041 (609)	796 (6)	4883	88	9.21%
West Bank & Gaza	8188	39541 (420)	306 (7)	7708	60	6.22%
Switzerland	8102	52871 (225)	2069 (4)	6098	239	3.35%
Guatemala	8076	90968 (705)	3238 (4)	5055	180	3.88%
Kuwait	7912	104568 (587)	607 (2)	24398	142	3.13%
Nigeria	7599	58647 (187)	1111 (0)	283	5	1.57%
Denmark	6494	27464 (392)	650 (1)	4737	112	11.31%
Japan	6492	83022 (538)	1568 (7)	653	12	3.63%
Bosnia	6061	27226 (225)	843 (14)	8312	257	4.21%
Sudan	6040	13640 (34)	836 (0)	309	19	0.45%
Bahrain	5909	70422 (574)	246 (1)	41052	143	4.84%

VERY HIGH RISK (>5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases/ 1M Pop	Deaths/ 1M Pop	% Daily Change 7-Day Av
Jordan**	5496	10049 (823)	57 (6)	982	6	39.87%
Albania	5402	13518 (127)	384 (4)	4699	133	5.41%
Bulgaria	5245	20547 (276)	813 (6)	2963	117	6.15%
Slovakia	5200	9574 (231)	45 (1)	1753	8	24.08%
Armenia**	5094	49901 (327)	958 (1)	16832	323	4.06%
Afghanistan	5050	39254 (21)	1458 (3)	1003	37	0.28%

** Indicates moved up a risk category

Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Country Risk Assessment

HIGH RISK (1,000-5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases / 1M Pop.	Deaths / 1M Pop	% Daily Change 7-Day Av
Jamaica	4537	6408 (238)	101 (8)	2162	34	15.81%
El Salvador	4457	28981 (172)	839 (8)	4463	129	3.54%
Uganda	3909	8017 (240)	75 (0)	174	2	14.19%
Georgia	3506	5866 (314)	36 (4)	1471	9	29.42%
Montenegro	3409	10575 (134)	164 (1)	16837	261	10.85%
Kosovo	3407	12683 (0)	488 (0)			0.00%
Kazakhstan	3309	107908 (75)	1725 (26)	5726	92	0.35%
Mozambique	3292	8556 (268)	59 (0)	272	2	15.12%
Belarus	3112	78260 (314)	828 (6)	8283	88	2.43%
Uzbekistan	2918	56354 (578)	466 (6)	1678	14	5.46%
CAR	2904	4806 (0)	62 (0)	991	13	0.08%
Angola	2893	4905 (108)	179 (3)	148	5	11.05%
Qatar	2871	125533 (222)	214 (0)	44709	76	1.08%
Syria	2863	4148 (46)	197 (3)	236	11	5.40%

HIGH RISK (1,000-5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases/ 1M Pop.	Deaths/ 1M Pop	% Daily Change 7-Day Av
Kyrgyzstan	2697	46522 (167)	1064 (0)	7102	162	1.92%
Norway	2451	13915 (127)	274 (0)	2562	50	4.58%
Botswana	2446	3172 (0)	16 (0)	1342	7	19.07%
Senegal	2300	14945 (26)	310 (1)	887	18	1.00%
N Macedonia	2248	17786 (112)	737 (8)	8537	354	4.14%
Guadeloupe	2246	4487 (0)	42 (0)	11214	105	0.00%
Lithuania	2146	4587 (97)	92 (0)	1688	34	14.28%
Nicaragua	2106	5170 (97)	151 (2)	778	23	1.88%
Namibia	2082	11140 (19)	121 (0)	4365	47	4.28%
Trinidad & Tobago	1935	4463 (77)	74 (2)	3186	53	7.33%
South Korea	1809	23812 (113)	413 (6)	462	8	1.98%
Haiti	1756	8740 (0)	227 (0)	764	20	1.08%
Bahamas	1740	3903 (65)	91 (2)	9902	231	7.30%
Azerbaijan	1702	40119 (58)	590 (2)	3948	58	1.48%

Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Country Risk Assessment

HIGH RISK (1,000-5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases / 1M Pop.	Deaths / 1M Pop	% Daily Change7-Day Av
Finland	1697	9892 (149)	345 (0)	1785	62	6.11%
Rwanda	1682	4836 (4)	29 (0)	371	2	1.18%
Slovenia	1656	5487 (99)	149 (0)	2639	72	14.45%
Zimbabwe	1487	7837 (21)	228 (0)	525	15	1.43%
Australia	1442	27078 (23)	886 (4)	1058	34	0.36%
South Sudan	1361	2700 (8)	49 (0)	241	4	1.33%
Malawi	1348	5772 (2)	179 (0)	300	9	0.45%
Gambia	1306	3579 (10)	112 (1)	1471	46	1.03%
Martinique	1172	1290 (0)	20 (0)	3438	53	0.00%
Luxembourg	1171	8431 (55)	124 (0)	13415	197	4.04%
Croatia	1158	16380 (135)	275 (3)	3996	67	6.35%
Guyana	1124	2846 (59)	78 (0)	3614	99	10.93%
Maldives	1123	10194 (37)	34 (0)	18778	63	3.03%
Tajikistan	1120	9726 (41)	75 (0)	1014	8	2.58%

Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

HIGH RISK (1,000-5,000 cases)

Country	Active Cases	Confirmed (New)	Deaths (New)	Cases/ 1M Pop.	Deaths/ 1M Pop	% Daily Change7-Day Av
Egypt**	1071	103079 (124)	5914 (13)	1003	58	0.68%
Malaysia	1062	11135 (101)	134 (0)	343	4	5.66%
Reunion	1049	3882 (0)	14 (0)	4328	16	9.81%
Congo (Brazzaville)	1032	5008 (0)	89 (0)	902	16	0.06%
Madagascar	1009	16377 (29)	229 (0)	588	8	1.28%

** Indicates moved up a risk category

US Risk Assessment

VERY HIGH RISK (>5,000 cases)

State	Active Cases	Confirmed (New)	Deaths (New)	Cases / 1M Pop.	Deaths / 1M Pop	% Daily Change 7-Day Av
California	799872	815654 (2943)	15782 (149)	20659	400	2.36%
Florida	690425	704568 (3266)	14143 (106)	32805	659	2.00%
New York	347856	457649 (1189)	33144 (4)	25294	1708	0.23%
Georgia	309312	316306 (1025)	6994 (33)	29791	659	1.94%
Illinois	284567	293448 (1366)	8881 (23)	23161	701	4.14%
Arizona	177427	218184 (674)	5632 (8)	29976	774	1.33%
New Jersey	153604	204563 (456)	16117 (10)	23458	1828	1.75%
Virginia	126584	147345 (901)	3185 (15)	17283	373	3.32%
Missouri	126126	128263 (852)	2137 (16)	21105	361	7.84%
Maryland	112856	124311 (431)	3946 (8)	20562	653	2.42%
Texas	90324	767264 (6066)	15902 (95)	27020	553	3.17%
Alabama	86454	153554 (571)	2517 (16)	31317	513	4.17%
Washington	84918	87042 (404)	2124 (24)	11800	279	3.84%
Nevada	75909	79595 (404)	1593 (8)	25841	517	3.50%

VERY HIGH RISK (>5,000 cases)

State	Active Cases	Confirmed (New)	Deaths (New)	Cases/ 1M Pop.	Deaths/ 1M Pop	% Daily Change 7-Day Av
South Carolina	71139	147634 (1179)	3359 (22)	28674	652	4.03%
Colorado	61489	70004 (535)	2046 (2)	12160	355	4.79%
Kansas	55648	58350 (387)	651 (7)	20531	224	6.01%
Kentucky	54894	67856 (917)	1170 (8)	15188	262	6.40%
Connecticut	43514	57329 (182)	4505 (2)	16080	1264	1.77%
Michigan	34697	136820 (1118)	7072 (21)	13700	708	4.06%
Pennsylvania	27250	163180 (1586)	8101 (13)	12750	641	3.58%
Oregon	27198	33291 (297)	555 (8)	7893	132	5.37%
Indiana	21533	119066 (744)	3612 (21)	17686	537	4.81%
North Carolina	21220	209136 (910)	3494 (49)	19940	333	6.04%
Rhode Island	21127	24556 (132)	1113 (3)	23180	1051	1.54%
Wisconsin	20270	119955 (2367)	1300 (17)	20602	223	11.69%
Iowa	19417	88235 (978)	1341 (17)	27781	421	6.08%
Idaho	19174	41434 (511)	464 (4)	23186	652	4.03%

Data Source: Johns Hopkins University

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

US Risk Assessment

VERY HIGH RISK (>5,000 cases)

State	Active Cases	Confirmed (New)	Deaths (New)	Cases / 1M Pop.	Deaths / 1M Pop	% Daily Change7-Day Av
Utah	16835	72136 (694)	457 (4)	22501	143	8.62%
Ohio	16416	152907 (1105)	4783 (37)	13094	411	4.02%
Tennessee	14246	194611 (879)	2420 (31)	28497	354	4.01%
Oklahoma	13244	86219 (1025)	1018 (11)	21789	257	7.03%
New Mexico	11860	29157 (172)	875 (2)	13905	417	4.01%
Nebraska	11479	45044 (466)	478 (6)	23286	247	6.14%
Massachusetts	10682	131584 (512)	9423 (8)	19091	1367	2.33%
Louisiana	10494	165624 (533)	5490 (10)	35627	1181	1.80%
Delaware	9297	20531 (142)	635 (1)	21084	652	3.41%
Minnesota	7995	98447 (809)	2072 (5)	17456	367	6.45%
Arkansas	6965	82755 (706)	1350 (21)	27422	447	5.79%

Data Source: Johns Hopkins University

HIGH RISK (1,000-5,000 cases)

State	Active Cases	Confirmed (New)	Deaths (New)	Cases/ 1M Pop.	Deaths/ 1M Pop	% Daily Change7-Day Av
Mississippi	4944	97638 (589)	2957 (36)	32807	994	3.14%
West Virginia	4010	15693 (177)	350 (8)	8756	193	7.51%
South Dakota	3684	21997 (259)	223 (5)	24865	252	10.74%
North Dakota	3651	21401 (418)	239 (5)	28083	314	11.31%
Montana	3454	12724 (311)	177 (3)	11905	166	14.24%
Alaska	3342	7722 (125)	56 (0)	10554	77	9.30%
District of Columbia	2559	15300 (36)	626 (2)	21679	887	1.63%
Hawaii	1941	12290 (87)	134 (2)	8680	95	4.89%
Wyoming**	1069	5821 (67)	50 (0)	10058	86	11.20%

** Indicates moved up a risk category

Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same.

Contacts

This summary is based on reports sourced from among the 75 countries in which Dentons currently serves clients as well as from firms in other locations, some of which will formally join Dentons later in 2020. We are pleased to share this complimentary summary and contemporaneous assessment, with the caveat that developments are changing rapidly. This is not legal advice, and you should not act or refrain from acting based solely on its contents. We urge you to consult with counsel regarding your particular circumstances.

To read additional analysis, visit the [Dentons Flashpoint portal](#) for insights into geopolitics and governance; industry and markets; cyber and security; science, health and culture; and economic and regulatory issues.

Karl Hopkins

Partner and Global Chief Security Officer
Dentons
Washington, DC

D +1 202 408 9225
karl.hopkins@dentons.com

Melissa Mahle

Senior Analyst
Dentons
Washington, DC

D +1 202 408 6383
melissa.mahle@dentons.com